<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3379801/" ref="ordinalpos=4672&amp;ncbi_uid=5044020&amp;link_uid=PMC3379801" image-link="/pmc/articles/PMC3379801/figure/NOS114F8/" class="imagepopup">Fig. 8. From: p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells. </a></div><br /><div class="p4l_captionBody">p16-Cdk4-Rb signaling pathway diagram. The components that were evaluated in this study and associated with response to PD0332991 therapy are highlighted in grey color-filled boxes.</div></div>